BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 15298614)

  • 1. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori and gastroesophageal reflux disease: friends or foes?
    Gisbert JP; Pajares JM; Losa C
    Hepatogastroenterology; 1999; 46(26):1023-9. PubMed ID: 10370661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori.
    Fallone CA; Barkun AN; Mayrand S; Wakil G; Friedman G; Szilagyi A; Wheeler C; Ross D
    Aliment Pharmacol Ther; 2004 Oct; 20(7):761-8. PubMed ID: 15379836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.
    Raghunath AS; Hungin AP; Mason J; Jackson W
    Aliment Pharmacol Ther; 2009 Feb; 29(4):431-9. PubMed ID: 19035981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
    Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
    Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
    Rauws EA
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):569-73. PubMed ID: 9513835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GERD and H. pylori: is there a link?
    Falk GW
    Semin Gastrointest Dis; 2001 Jan; 12(1):16-25. PubMed ID: 11215851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
    Delaney B; McColl K
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
    Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
    Wong CH; Chua CJ; Liam CK; Goh KL
    Aliment Pharmacol Ther; 2006 May; 23(9):1321-7. PubMed ID: 16629937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
    Bergman MP; Klinkenberg-Knol EC; Faller G; Aar A; Lakhai W; Vandenbroucke-Grauls CM; Kuipers EJ; Appelmelk BJ
    Aliment Pharmacol Ther; 2005 Apr; 21(8):977-83. PubMed ID: 15813833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
    van Grieken NC; Meijer GA; Weiss MM; Bloemena E; Lindeman J; Baak JP; Meuwissen SG; Kuipers EJ
    Am J Gastroenterol; 2001 Oct; 96(10):2882-6. PubMed ID: 11693321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.
    Kountouras J; Chatzopoulos D; Zavos C; Boura P; Venizelos J; Kalis A
    Hepatogastroenterology; 2002; 49(43):193-7. PubMed ID: 11941952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The possible role of Helicobacter pylori in GERD.
    Falk GW
    Semin Gastrointest Dis; 2001 Jul; 12(3):186-95. PubMed ID: 11478751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.